• linkedin
  • Increase Font
  • Sharebar

    Leukemia drug may help fight skin cancer

    DT-eNews-Issue_402.jpg

    The leukemia drug dasatinib may prove useful for treating skin, breast and other cancers, according to recent findings.

    Researchers with Loyola University Chicago Stritch School of Medicine found that dasatinib, when applied to cancer cells in a laboratory setting, causes a cell-cell adhesion and halts cell migration, according to a news release. When used to treat leukemia, dasatinib targets the protein BCR-ABL, which is similar to the Fyn protein found in cancers such as those of the skin, brain, breast and pancreas. Dasatinib did not eliminate Fyn, but it did inhibit its activity, researchers found.

    In mice with skin cancer, dasatinib helped to reduce the number and size of their tumors, investigators noted.

    “Topical dasatinib treatment significantly reduced total tumor burden of the SKH1 mouse model of UV-induced skin carcinogenesis,” study authors wrote. “These results identify the promotion of actin-based cell-cell adhesion as a newly described mechanism of action for dasatinib and suggest Fyn inhibition may be an effective therapeutic approach in treating cSCC.”

    Clinical trials will test dasatinib on patients with melanoma, pancreatic cancer, prostate cancer, ovarian cancer, endometrial cancer, gastrointestinal stromal cancer, Hodgkin’s lymphoma, multiple myeloma and acute lymphoblastic leukemia.

    The findings were published online June 29 in Molecular Carcinogenesis.

    Related content:

    Researchers shed light on hereditary melanoma

    Latest updates on aBCC studies

    'Chaos' algorithm simplifies biopsy decision

    Sarah Thuerk
    Sarah Thuerk is associate editor of Healthcare Traveler magazine.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow